Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Discover more on how Polpharma API meets evolving regulatory guidance around N-nitrosamines control in APIs with Waters’ high-performance analysis instruments.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
Whitepapers/App Notes/Posters

Application Note: Multiparameter profiling of a Structure Activity Relationship (SAR) library for immunological activity in human PBMCs

Posted: 15 January 2016 | | No comments yet

We describe a no-wash, high throughput screen that provides a multiparametric activity profile for a structure activity relationship (SAR) library derived from immunomodulatory compounds…

The success of immunomodulatory approaches for the treatment of disease has generated tremendous interest in discovery of new immunotherapy based therapeutics. Immunotherapy has the potential of affecting – positively and negatively – the myriad interactions among cells and signaling molecules regulating the immune system, and projects should include high throughput screening campaigns aimed at profiling the effects of compounds on these complex interactions.

We describe a no-wash, high throughput screen that provides a multiparametric activity profile for a structure activity relationship (SAR) library derived from immunomodulatory compounds.

Methods

Seven known immunomodulatory compounds were used as templates to generate an SAR expansion library of 1438 compounds. The selection utilised a combination of various substructure and similarity search methods combined with the generation of virtual templates.

This application note is restricted - login or subscribe free to access

EPR Issue 1 2024Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 

Related topics

Related organisations